Compass COMP 深 滬
等待開盤 09-24 09:30:00 美东时间
9.16
-0.510
-5.27%
華盛通- 最 高9.66
- 今 開9.50
- 成交量 1808.80万股
- 最 低 9.055
- 昨 收 9.67
- 總市值 69.39亿
- 52周最高 13.955
- 市盈率 靜 --
- 換手率 2.39%
- 52周最低 6.37
- 委 比 99.23%
- 總股本 7.58亿
- 歷史最高 22.11
- 量 比 0.96
- 振 幅 6.26%
- 歷史最低 1.815
- 每 手 1
- 風險率 1.88%
個股概要
財務分析
公司資料
相關新聞
分紅派息
- 分時圖
- 日k
- 周k
- 月k
相關新聞
更多Mortgage Rates Top 7% for the First Time Since 2024: 5 Stocks Most at Risk
Homebuilder stocks had one of their best days in months on Tuesday. By Wednesday morning, the mortgage data served a cold shower. The Mortgage Bankers Association (MBA) reported that the average 30-year fixed mortgage rate had risen to 7.12% in the week ending Sept. 18. The iShares U.S. Home Constru...
09-23 22:06
Compass Therapeutics Craters, FDA Pushes Survival-Trial Demand for Cancer Drug
Compass Therapeutics, Inc. (NASDAQ:CMPX) shares are trading lower on Tuesday as the FDA feedback raises new questions about the timing and requirements for its tovecimig program. The move is coming even as S&P 500 futures are up 0.1%, pointing to stock-specific pressure rather than a broad risk-off ...
09-23 02:02
43年「罗盘呼叫」谢幕：美空军退役EC-130H电子战飞机，喷气式EA-37B接班
无人机 · 编译 无人机 · 编译 ｜ 电子对抗 · 空中电子攻击 ｜ 2026年9月22日 据Defence Blog记者...
09-22 16:48
Compass Pathways Announces U.S. Healthcare Provider Grant Program Recipients To Create Training For Delivery Of Psychedelic Treatments
These programs are intended to address both the need for foundational training in psychedelics, as well as ensuring HCPs are well-prepared to care for patients receiving treatment with COMP360 following its expected commercial launch, if approved. The recipients were selected through a competitive a...
09-10 18:41
Compass Pathways’ Psilocybin Treatment Shows Lasting Benefits in Treatment-Resistant Depression
Compass Pathways plc (NASDAQ:CMPS) on Wednesday shared topline 52-week Part C results from its Phase 3 COMP005 study evaluating COMP360, a proprietary synthetic formulation of psilocybin, for treatment-resistant depression. Following the announcement, the stock jumped over 11%. The updated data rein...
09-10 01:18
Maze Therapeutics to Participate in Three Upcoming Investor Conferences
Maze Therapeutics announced its participation in three upcoming investor conferences: the Wells Fargo 21st Annual Healthcare Conference on September 9, 2026; the Citi 2026 Biopharma Back to School Summit on September 10, 2026; and the H.C. Wainwright 28th Annual Global Investment Conference on September 15, 2026. Live webcasts will be available on the company's website, www.mazetx.com, and archived for 60 days. Maze Therapeutics is a clinical-sta...
09-02 11:00
VINCI COMPASS COMPLETES THE ACQUISITION OF NAVI'S REAL ESTATE PLATFORM
RIO DE JANEIRO, Sept. 1, 2026 /PRNewswire/ -- Vinci Compass Investments Ltd. (NASDAQ: VINP) ("Vinci Compass," "we," "the Company," "us," or "our"), the controlling company of a leading alte...
09-02 04:02
Deutsche Bank Maintains Buy on Compass Minerals Intl, Lowers Price Target to $32
Deutsche Bank analyst David Begleiter maintains Compass Minerals Intl (NYSE:CMP) with a Buy and lowers the price target from $35 to $32.
09-01 01:55
IREN(IREN.US)Q2电话会：供需结构性缺口正持续扩大，垂直整合全栈能力成护城河
数据中心及AI云服务商IREN Limited于8月27日盘后发布2026财年第四季度业绩报告。IREN在2026财年第四季度业绩电话会披露，公司AI云转型已进入收获期。
08-28 14:46
Priovant Announces FDA Approval of LISRAYA™ (brepocitinib) for Adults with Dermatomyositis; Now Available in the U.S.
LISRAYA, a first-in-class TYK2/JAK1 inhibitor, has been approved by the FDA for the treatment of adults with dermatomyositis (DM), a debilitating autoimmune disease. As the first targeted therapy for DM, LISRAYA offers significant benefits, including improved skin disease, muscle strength, and reduced steroid dependency. The approval follows successful Phase 3 trials, with the largest DM trial ever conducted demonstrating substantial efficacy and...
08-27 19:28
